Overview

Safety and Effect of Intravitreal Delivery of Zidovudine Derivative, K8, in Subjects With Diabetic Macular Edema

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This study is designed to assess the safety and initial evidence of efficacy of the novel compound K8, a zidovudine (AZT) derivative, in subjects with untreated, clinically significant, diabetic macular edema (DME).

Phase:

Phase 1

Details

Lead Sponsor:

Michelle Abou-Jaoude

Collaborator:

Inflammasome Therapeutics

Treatments:

Zidovudine